---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-050334"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:50:46.422218+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Beam reports positive initial Phase 1/2 data for BEAM-302 in AATD; total AAT exceeds protective threshold

## Summary
- BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.
- Single 60 mg dose achieved mean total AAT of 12.4 µM at Day 28, exceeding 11 µM protective threshold.
- Mutant Z-AAT reduced up to 78% from baseline at 60 mg dose level.
- First clinical evidence of precise genetic correction of a disease-causing mutation via base editing.
- Dose escalation to continue; further data expected at medical conference in H2 2025; Part B dosing planned H2 2025.

## SEC filing metadata
- accession: 0001193125-25-050334
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312525050334/0001193125-25-050334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312525050334/d922493d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-050334
- JSON: https://secwatch.observer/filing/0001193125-25-050334.json
- Plain text: https://secwatch.observer/filing/0001193125-25-050334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.